ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

3:00PM-4:30PM: Abstract Number: 0874

Defining a Protective Role for Mucosal-associated Invariant T (MAIT) Cells in Spontaneous Cutaneous Lupus Erythematosus

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 0867

Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)

3:00PM-4:30PM: Abstract Number: 0851

Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 0871

Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)

3:00PM-4:30PM: Abstract Number: 0835

Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 0844

Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis

Abstracts: Epidemiology & Public Health I

3:00PM-4:30PM: Abstract Number: 0849

Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 0873

Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 0829

Epstein-Barr Virus Infection Triggers Hyperinflammation and Cytokine Storm in Healthy Children

Abstracts: Pediatric Rheumatology – Basic Science

3:00PM-4:30PM: Abstract Number: 0834

Evolution of Lung Inflammation in a Mouse Model of Chronic/Recurrent Macrophage Activation Syndrome

Abstracts: Pediatric Rheumatology – Basic Science

3:00PM-4:30PM: Abstract Number: 0857

Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0843

External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors

Abstracts: Epidemiology & Public Health I

3:00PM-4:30PM: Abstract Number: 0848

Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchicine Among Gout Patients with Type 2 Diabetes:Propensity-Score Matched, Active Comparator, New User Design Study

Abstracts: Epidemiology & Public Health I

3:00PM-4:30PM: Abstract Number: 0859

Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0860

Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].